Background and objective: Lymphangioleiomyomatosis (LAM) is a diffuse cystic lung disease that occurs in women of childbearing age. LAM can be diagnosed on a clinical basis in patients with typical high-resolution computed tomography (HRCT) patterns and at least one other corroborating disease feature, such as chylothorax, angiomyolipoma, tuberous sclerosis complex or elevated serum vascular endothelial growth factor (VEGF)-D. However, patients who do not meet these criteria require tissue confirmation for a definitive diagnosis, and the utility of methods that are less invasive than surgical lung biopsy, such as transbronchial lung biopsy (TBLB), are not well studied. We retrospectively studied the efficacy and safety of TBLB for the diagnosis of LAM. Methods: From January 1991 to August 2015, 131 consecutive LAM patients were prospectively registered in our study, and a TBLB was conducted for 24 patients. We retrospectively studied the yield and safety of TBLB in this cohort. Results: All 24 patients were women; the median age was 42 years. HRCT showed multiple round thin-walled cysts diffusely scattered throughout the lungs. The median level of serum VEGF-D was 2109 pg/mL. Characteristic pathological findings for LAM were identified in 17 patients (70.8%) by two expert pathologists. The % predicted value for diffusing capacity of carbon monoxide was significantly lower in the 17 TBLB-positive LAM patients compared to the seven TBLB-negative LAM patients (P = 0.046). There were no serious adverse events such as pneumothorax or uncontrollable bleeding due to TBLB. Conclusion: TBLB is a safe and effective method for the pathological diagnosis of LAM.
INTRODUCTION
Lymphangioleiomyomatosis (LAM) is a rare lung disease of women caused by smooth muscle cell infiltration and cystic remodelling of pulmonary parenchyma. 1 LAM is considered to be a low-grade, destructive, metastasizing neoplasm 2 that occurs in a subset of women who have tuberous sclerosis complex (TSC) and as a sporadic illness in females from the general population who do not have that heritable illness. 1 Mutations in TSC genes are known be involved in disease pathogenesis in both the TSC-associated and sporadic forms 
SUMMARY AT A GLANCE
The diagnosis yield for lymphangioleiomyomatosis by transbronchial lung biopsy (TBLB) was 70.8%. The yield of TBLB was higher in patients with a reduced diffusing capacity, suggesting that an adequate disease burden is required for this approach. The procedure seems safe, as no serious adverse events such as pneumothorax or excessive bleeding were observed. of LAM. Pneumothorax and progressive dyspnoea on exertion are common disease manifestations, and hypoxemia requiring supplemental oxygen therapy and respiratory failure often result from progressive deterioration of lung function.
As LAM is a rare disease with protean manifestations, the diagnosis is often delayed. LAM is suspected when a patient presents with a characteristic highresolution computed tomography (HRCT) pattern of multiple bilateral lung cysts, and can be confirmed based on clinical grounds if any additional disease manifestation is present, such as chylous pleural effusion, chylous ascites, TSC, renal angiomyolipoma and/or lymphangioleiomyoma of the lymph nodes are also present. 3, 4 Recently, it was reported that serum vascular endothelial growth factor (VEGF)-D level is also a useful biomarker for diagnosis, and a value of greater than 800 pg/mL can substitute for the clinical features above in the diagnostic algorithm. 4, 5 Minimally invasive techniques of transcutaneous needle aspiration of enlarged axial lymph nodes, or thoracentesis for identification of LAM cell clusters in chylous fluid can occasionally provide adequate cellular material for diagnosis in certain patients. 6 In the absence of these clinical, serological, cytological or radiological findings, a lung biopsy is required for a definite pathological diagnosis of LAM.
Although transbronchial lung biopsy (TBLB) is widely performed for the diagnosis of lung diseases, its effectiveness and safety in LAM patients have not been well studied. Surgical lung biopsy (SLB) is the gold standard for the pathological diagnosis of LAM. 7, 8 Although SLB has a higher diagnostic yield than TBLB due to the size of specimens that can be obtained, it is also associated with the risks of general anaesthesia, and with greater potential for post-operative complications such as prolonged air leak and thoracic pain. 9, 10 We postulated that TBLB is an effective and safe method for establishing the diagnosis of LAM. In addition, we analysed features associated with the yield of TBLB for LAM, including pulmonary function test data and HRCT characteristics, and found that diffusing capacity can be useful for selecting patients who are likely to benefit from the procedure.
METHODS

Study population
From January 1991 to August 2015, 131 consecutive patients were diagnosed with LAM and prospectively registered in the LAM cohort database of the National Hospital Organization Kinki-Chuo Chest Medical Center (KCCMC) (Fig. 1) . All patients were diagnosed using HRCT images showing multiple bilateral cystic shadows compatible with LAM, and at least one of the following additional criteria: confirmation of LAM cells with a biopsy, a serum VEGF-D level of ≥800 pg/mL or clinical history of chylous pleural effusion, renal angiomyolipoma, or an existing diagnosis of TSC. 4, 11 In this study, 24 consecutive LAM patients that received TBLB at the KCCMC were enrolled (Fig. 1 
Transbronchial lung biopsy
TBLB was performed using an Olympus BF-1T260 (Olympus Corporation, Shinjuku-ku, Tokyo, Japan), with alligator forceps. Physicians attempted to collect at least three specimens per lobe from the upper and Figure 1 Diagnostic process for LAM at the National Hospital Organization KCCMC. In the KCCMC LAM database, 131 consecutive patients were diagnosed with LAM and prospectively registered. TBLB was conducted in 24 patients at the KCCMC, and LAM cell nests were detected in 17 patients (confirmed TBLB-positive). * One LAM patient who underwent SLB at another facility underwent TBLB at the KCCMC. KCCMC, Kinki-Chuo Chest Medical Center; LAM, lymphangioleiomyomatosis; SLB, surgical lung biopsy; TBLB, transbronchial lung biopsy.
lower lobes of one lung. Bronchoalveolar lavage was routinely performed in the right middle lobe using a volume of 150 mL during the procedure.
Pathology
The specimens were analysed by two LAM expert pathologists. One of the pathologists (M.K.) made the diagnosis at the time the TBLB was conducted, and the second (T.K.) retrospectively reviewed the specimens for the purpose of this study.
The histological criteria used for the diagnosis of LAM in patients who underwent TBLB were as follows [13] [14] [15] [16] [17] [18] [19] [20] : 1. Presence of one or more spindle cell nests (LAM cell nests) by haematoxylin and eosin staining. 2. Presence of one or more yellow-stained smooth muscle cell nests (LAM cell nests) in the pulmonary interstitium using Weigert's method. 3. Positive immunohistochemical staining for alphasmooth muscle actin (SMA). 4. Positive immunohistochemical staining for oestrogen receptors (ER) or progesterone receptors (PgR).
Positive immunohistochemical staining for HMB-45
(Human Melanoma Black-45).
The histopathological diagnosis of LAM was made upon confirmation of criteria 1 through 4. The findings of criterion 5 were considered helpful but not mandatory. Stains for desmin and hemosiderin were also performed, but were not part of the diagnostic algorithm.
Pulmonary function tests and HRCT
All pulmonary function tests were performed using a CHESTAC-8800 or 8900 (CHEST, Bunkyo-ku, Tokyo, Japan). Diffusing capacity of carbon monoxide (DL CO ) was measured using the single-breath method with correction for haemoglobin, and total lung capacity and residual volume were determined with the closed circuit helium dilution technique. 21 All quantitative HRCT examinations were performed using a 16 multi-detector CT scanner (HiSpeed Ultra 16; GE Healthcare, Chicago, IL, USA). Percentage lung volume with less than −950 Hounsfield units at full inspiration (LAV%) was calculated to quantify low lung attenuation that is associated with cystic change in the lung. 22 
Statistical analysis
The Pearson's chi-square test or the Wilcoxon rank sum test was used to compare patients in which LAM cells were detected by TBLB (hereafter referred to as TBLB-positive patients) with those in which they were not (TBLB-negative patients). A correlation between two parameters was calculated using the Spearman's rank correlation coefficients. In all tests, statistical significance was inferred at P < 0.05. Statistical analyses were conducted using JMP v. 8.0 (SAS Institute, Cary, NC, USA).
RESULTS
Patient demographics
Among the 131 LAM patients registered in the database, 24 underwent TBLB at the KCCMC (Fig. 1 , Table 1 ). All patients were female. All included patients of suspected LAM referred for TBLB were eventually confirmed to have that disease: 23 patients had sporadic-LAM, and one had TSC-LAM. HRCT images of all 24 patients showed multiple bilateral round thinwalled cystic shadows scattered throughout the lungs. One patient had new ground glass density that was being investigated with TBLB. Seven patients had a prior history of pneumothorax (Table 1) . The median serum VEGF-D level was 2109 pg/mL, including 22 patients (91.7%) with a level >800 pg/mL 4, 5 (Table 1 ). There were no significant differences in baseline patient characteristics between TBLB-positive and TBLB-negative patients (Table 1) .
TBLB was routinely performed with patients receiving supplemental oxygen ≤5 L/min. In no patient did a supplemental oxygen requirement persist beyond the morning following the procedure, except one woman who had presented on long-term oxygen therapy of 2 L/min at rest.
LAM cells detection ratio by TBLB and pathological findings
LAM cell nests were detected by TBLB in 17 of the 24 patients (70.8%). In the seven of TBLB-negative patients, the diagnosis of LAM was based on SLB in three; the presence of a lymphangioleiomyoma in one; the pathological diagnosis of a renal angiomyolipoma in one and on typical HRCT findings and elevated serum VEGF-D levels in two. For the two patients (of the 24 patients) with a serum VEGF-D level of <800 pg/mL, one was TBLB-positive and the diagnosis of LAM in TBLB-negative patient was based on the pathological diagnosis of renal angiomyolipoma.
The median number of lung specimens obtained was five for both TBLB-positive (range, 2-7) and TBLBnegative patients (range 3-6; Table 1 
Low %predicted DL CO correlates with LAM cells detection by TBLB
The %predicted DL CO was significantly lower in TBLBpositive patients than in TBLB-negative patients (P = 0.046; Table 2 ). The receiver operating characteristic curve for predicting a LAM cell detection based on %predicted DL CO is shown in Figure 2 . The cut-off % predicted DL CO value for predicting the observed result was 66.4% (sensitivity 76.5%, specificity 83.3%). There were no significant differences in the other pulmonary function tests or the LAV% on HRCT between the TBLB-positive and TBLB-negative patients.
Safety of TBLB
In this study population, no serious adverse events such as pneumothorax or excessive bleeding resulting from TBLB were observed. After anaesthesia was administered by aerosolizing topical lidocaine and before initiation of bronchoscopy, one patient had an episode of hyperventilation and another had vagal reflex. Both resolved spontaneously with reassurance. Two episodes of limited bleeding occurred, managed with topical endobronchial epinephrine. Sixteen patients were prescribed preventative oral antibiotics for 3 days after bronchoscopy at the physician's discretion, which is a practice that is common at our institution following TBLB. Six patients experienced transient fever of <37. 5 C in the first 24 h after bronchoscopy. One patient had a fever of 38.0 C for 2 days after %Predicted DL CO was significantly lower in TBLB-positive patients than in TBLB-negative patients (P = 0.046). There were no significant differences in the other pulmonary function tests or LAV% on HRCT between the TBLB-positive and TBLB-negative patients. However, %predicted DL CO was correlated significantly with the pulmonary function tests, such as FEV 1 /FVC (P = 0.020), FEV 1 (P < 0.001), RV/TLC (P = 0.022) and LAV% (P = 0.003) using the Spearman's rank correlation coefficients.
† The Wilcoxon rank sum test was used to compare TBLB-positive and TBLB-negative patients. ‡ n = 23. § n = 6. ¶ n = 22. † † n = 16. DL CO , diffusing capacity of carbon monoxide; FEV 1 , forced expiratory volume in 1 s; FVC, forced vital capacity; LAM, lymphangioleiomyomatosis; LAV%, percentage lung volume with less than −950 Hounsfield units at full inspiration; RV, residual volume; TLC, total lung capacity; TBLB, transbronchial lung biopsy.
bronchoscopy, but no additional therapy other than preventative oral antibiotics was needed.
A typical example of a LAM patient who underwent TBLB is presented. This 42-year-old woman with diagnosed LAM based on the presence of TSC manifestations underwent the procedure with no adverse events. Her chest radiograph, HRCT images and lung specimens are shown in Figure 3 .
DISCUSSION
In this study, we report that TBLB is an effective and safe method to obtain tissues for the pathological diagnosis of LAM with a yield of 70.8%, and no serious adverse events observed in a cohort of 24 patients.
A general principle in the care of LAM patients is that the diagnosis should be made using the least invasive method available. Although American Thoracic Society/Japanese Respiratory Society (ATS/JRS), 4 and European Respiratory Society criteria 3 allow for the diagnosis of LAM to be made on clinical grounds for most patients, a small but important subset (perhaps 15-25% of patients) require cytological or pathological confirmation. SLB has been the standard approach in the majority of these patients, but it is associated with significant morbidity and mortality.
Although previous studies reported that TBLB can be diagnostic, there are no reports of the yield of the approach in series that included more than 20 LAM patients, and few that studied consecutive patients. Torre et al. reported that six of seven TBLBs were diagnostic, 23 which was the largest report with a diagnostic yield in consecutive patients with LAM. In a clinicopathological study of 46 LAM patients reported by Kitaichi et al., six patients were pathologically diagnosed with LAM based on TBLB specimens. 20 In the recent nationwide Japanese study of 173 LAM patients reported by Hayashida et al., LAM diagnoses were obtained using pathological findings of lung biopsy in 144 patients (83%), and 18 of these were diagnosed by TBLB. 24 Ye et al. found that among the 97 pathologically confirmed LAM patients reported in academic papers published in mainland China, 49 were diagnosed by TBLB, 25 although they did not specifically report the yield or the adverse events. Meraj et al. reported that LAM cells were detected in the TBLB specimens from 35 of 63 LAM patients (56%), based on data collected in two online surveys sent to over 1000 LAM patients registered with the LAM Foundation. 26 The results were self-reported by e-mail accessible patients, and by the author's acknowledgement were therefore biased by sampling and patient recall.
The disease severity of LAM is usually assessed with pulmonary function tests. 4, 11, 20, 27 Avila et al. reported that pulmonary function tests correlated with quantitative thin-section computed tomography (CT) in LAM patients. 28 We hypothesized that it would be easier to detect LAM cell nests in TBLB specimens from patients with more severe disease (worse pulmonary function and higher LAV%) than those with milder disease. We found that TBLB-positive patients had lower %pre-dicted DL CO than TBLB-negative patients. However, we did not find a correlation between the yield of TBLB and other pulmonary function parameters or LAV% in our cohort. The correlation between disease severity and yield in TBLB specimens must be tested in a larger study.
In general, at least five to six biopsy specimens from unique sites should be obtained in order to optimize the diagnostic yield of TBLB in patients with diffuse lung diseases; more specimens enhance diagnostic sensitivity and specificity at the expense of added risk. 29, 30 We attempted to obtain six specimens from each patient, although at times, specimen collection was truncated due to concerns of pneumothorax. As a result, the median number of our assessable specimens was five for both the TBLB-positive and TBLB-negative patients.
Torre et al. reported no adverse events in the seven patients, 23 which were the only data regarding adverse events from consecutive TBLBs in LAM patients. Notably, none of our 24 LAM patients experienced a pneumothorax. Although pulmonary physicians should be mindful of the risk of pneumothorax in patients with cystic lung diseases, including LAM, there is little or no data supporting excessive risk for this complication in patients with diffuse cystic lung disease. TBLB is known to pose risk for subjects who have limited respiratory reserve however, and care should be taken in the selection of candidates for TBLB. In our series, one patient required continuous oxygen on rest, and she tolerated the procedure well. Inclusion and exclusion criteria for the use of TBLB should be developed in the future using data from multiple centres.
Taylor et al. reported that in their study of 32 LAM patients, the presence of LAM cells were not identified Figure 2 Receiver operating characteristic curve for prediction of the detection ratio of LAM cell nests based on the %predicted value for DL CO (%predicted DL CO ; n = 23). The area under the curve was 0.784. The cut-off %predicted DL CO value for prediction of the observed detection ratio of LAM cell nests in TBLB specimens was 66.4% (sensitivity 76.5%, specificity 83.3%). DL CO , diffusing capacity of carbon monoxide; LAM, lymphangioleiomyomatosis; TBLB, transbronchial lung biopsy. in the pathological specimens of any of the five patients who underwent TBLB. LAM was recognized more readily in open-lung biopsy specimens from that cohort; 26 of 30 specimens (87%) were interpreted as diagnostic of LAM on initial examination. 31 TBLB has a more favourable risk profile than SLB, [7] [8] [9] [10] and our study demonstrates that using modern histological techniques and criteria, the diagnosis can made using this less invasive approach in the majority of patients.
This study began in the era before diagnostic criteria for LAM were well established, and many of the patients who were selected for TBLB based on clinical practice at the time would not have required the procedure today. Recent progress in the diagnostic approach to LAM was summarized and reported in the official ATS/JRS guidelines for LAM. 4 The guidelines recommend VEGF-D testing before consideration of diagnostic lung biopsy for patients whose HRCT scans show cystic abnormalities characteristic of LAM but have no confirmatory clinical or extrapulmonary radiological features. In that setting, a serum VEGF-D threshold of 800 pg/mL has a sensitivity and specificity of 73% and 99% for the diagnosis of LAM, respectively. The rationale for using a threshold of 800 pg/mL rather than 600 pg/mL (which also has excellent test performance characteristics) is to minimize false-positive results, but this higher cut-off will also result in a larger number of patients referred for lung biopsy for diagnostic confirmation.
In conclusion, we find that TBLB is a safe and effective method for the pathological diagnosis of LAM. We recommend that this procedure be considered before referral for SLB in selected patients with clinical features that predicts acceptable yield, such as those with at least a moderate profusion of cystic change on CT or abnormal DL CO .
